BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf 2020;19:673-82. [PMID: 32521174 DOI: 10.1080/14740338.2020.1764532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Han J, Xie S, Jiao H. Sodium-glucose cotransporter-2 inhibitor-induced euglycemic diabetic ketoacidosis: A case report. J Clin Pharm Ther 2022. [PMID: 35949163 DOI: 10.1111/jcpt.13737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Sohatee M, Holland J. Life-threatening complications for diabetic patients taking SGLT2 inhibitors when undergoing surgery: A poorly recognised problem? J Perioper Pract 2022;:17504589211024409. [PMID: 35291825 DOI: 10.1177/17504589211024409] [Reference Citation Analysis]
3 Wang Q, Wu K, Luo X, Dong X, Liu W, Tang Z, Zhang B. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis. Cureus 2022. [DOI: 10.7759/cureus.22229] [Reference Citation Analysis]
4 Bai Y, Jin J, Zhou W, Zhang S, Xu J. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 2021;31:1365-74. [PMID: 33812735 DOI: 10.1016/j.numecd.2021.02.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clin J Am Soc Nephrol 2021;16:1284-91. [PMID: 33563658 DOI: 10.2215/CJN.17621120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
6 Osaka N, Kushima H, Mori Y, Saito T, Hiromura M, Terasaki M, Yashima H, Ohara M, Fukui T, Matsui T, Hirano T, Yamagishi SI. Anti-inflammatory and atheroprotective properties of glucagon. Diab Vasc Dis Res 2020;17:1479164120965183. [PMID: 33076703 DOI: 10.1177/1479164120965183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sampani E, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, Papanikolaou A, Papagianni A. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC Nephrol 2020;21:276. [PMID: 32669085 DOI: 10.1186/s12882-020-01930-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]